Want to see JP:219A full AI Analyst Report?
219A Stock Chart & Stats
¥1804.00
-¥95.00(-2.73%)
At close: 4:00 PM EST
¥1804.00
-¥95.00(-2.73%)
Day’s Range― - ―
52-Week Range¥1,343.00 - ¥3,925.00
Previous CloseN/A
Volume1.41M
Average Volume (3M)738.74K
Market Cap
¥38.53B
Enterprise Value¥32.19K
Total Cash (Recent Filing)¥7.34B
Total Debt (Recent Filing)¥890.00K
Price to Earnings (P/E)37.5
Beta1.24
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)25.93
Shares Outstanding22,893,400
10 Day Avg. Volume469,170
30 Day Avg. Volume738,736
Financial Highlights & Ratios
PEG Ratio-2.00
Price to Book (P/B)5.17
Price to Sales (P/S)12.93
P/FCF Ratio37.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-94.5
Revenue Forecast (FY)¥451.00M
Bulls Say, Bears Say
Bulls Say
Low LeverageExtremely low leverage provides durable financial flexibility: it lowers refinancing and interest risk, supports continued R&D or clinical programs without urgent external funding, and gives management optionality for opportunistic M&A or capital deployment during industry cycles.
Cash Flow TurnaroundA return to positive operating and free cash flow indicates the business can self-fund near-term operations and reduce dilution risk. If sustained, consistent cash generation supports ongoing clinical development, commercialization scaling, and lowers reliance on capital markets across the next several quarters.
Profitability & GrowthA meaningful revenue lift combined with strong margins suggests improving commercial traction and more scalable economics. Sustained mid-teens+ margins would support reinvestment and shareholder returns and indicate the firm can convert growth into durable profits rather than transient top-line spikes.
Bears Say
Historic Cash BurnA multi-year history of losses and cash burn signals execution and profitability volatility. This legacy increases the risk that the FY2025 turnaround could be cyclical; it also implies the company has previously needed external funding, which could recur under adverse outcomes or growth setbacks.
Inconsistent Gross ProfitInconsistent or unclear gross-profit reporting undermines confidence in core unit economics and margin comparability. That opacity makes it harder to model sustainable margins and predict long-term profitability, raising forecasting risk for investors and management planning.
Turnaround Sustainability RiskManagement must sustain revenue growth and cash conversion to lock in the FY2025 gains; if clinical setbacks or slower commercialization occur, the firm could revert to cash burn. That structural sensitivity raises funding and execution risk over the next several quarters.
Heartseed, Inc. News
219A FAQ
What was Heartseed, Inc.’s price range in the past 12 months?
Heartseed, Inc. lowest stock price was ¥1343.00 and its highest was ¥3925.00 in the past 12 months.
What is Heartseed, Inc.’s market cap?
Heartseed, Inc.’s market cap is ¥38.53B.
When is Heartseed, Inc.’s upcoming earnings report date?
Heartseed, Inc.’s upcoming earnings report date is Aug 14, 2026 which is in 9 days.
How were Heartseed, Inc.’s earnings last quarter?
Currently, no data Available
Is Heartseed, Inc. overvalued?
According to Wall Street analysts Heartseed, Inc.’s price is currently Overvalued.
Does Heartseed, Inc. pay dividends?
Heartseed, Inc. does not currently pay dividends.
What is Heartseed, Inc.’s EPS estimate?
Heartseed, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Heartseed, Inc. have?
Heartseed, Inc. has 22,893,400 shares outstanding.
What happened to Heartseed, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Heartseed, Inc.?
Currently, no hedge funds are holding shares in JP:219A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Heartseed, Inc.
Headquartered in Tokyo, Japan, Heartseed, Inc. was established on November 30, 2015, by Keiichi Fukuda, Takumi Akiyama, Toshiharu Furukawa, and Yutaro Kasai. The company specializes in the development and advancement of cardiac regenerative medicine.
Technical Analysis
Pharmarise Holdings Corp.
―
COSMOS Pharmaceutical Corporation
―
Medical System Network Co., Ltd.
―
Shinnihonseiyaku Co., Ltd.
―
Chordia Therapeutics Inc.
―